Pivastalo. Действие презентация

Pivastalo Finding it’s Place in therapy
Differentiation in
Pharmacological Action
Pleiotropic effect
Prevention of major CV events
Lower Drop out rate
Patient adherence
Pivastalo
The Hidden Gem
®

Pivastalo
The Hidden Gem
®
Pivastalo
A distinctive lipid lowering drug
®
Pivastalo is characterized by a cyclopropyl moiety
that results in Superior Clinically efficacy and Safety profile.
The Lowest Statin Dose *1
Providing inhibition of cholesterol synthesis and increased lipoprotein lipase expression
The Highest Bioavailability
Pivastalo has a higher bioavailability
(60%-80%) than any other statin
Minimal drug–drug and drug–food interactions
*2
*2
Metabolism by CYP2C9 and not metabolized by CYP3A4

Pivastalo
The Hidden Gem
®
Effective, first-line therapy that offers an alternative, simple treatment regimen in the
long-term care of primary hypercholesterolemia and combined dyslipidemia.
Pivastalo
Effective lipid lowering drug
Dragos Budinski, Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia Clin. Lipidol. (2009)

Pivastalo
Neutral effect on Glycemic Control
The cumulative incidence of ( New Onset of Diabetes Mellitus )NODM
was significantly lower in Pivastalo group Compared with the atorvastatin and rosuvastatin groups
Pivastalo
The Hidden Gem
®
JahYeonChoi, Effect of Pitavastatin Compared with Atorvastatin and Rosuvastatinon
New-Onset Diabetes Mellitus in Patients With Acute Myocardial Infarction, Am J Cardiol 2018
John Jp Kastelein, Pitavastatin: an overview of the LIVES study Clin. Lipidol. (2012)

Pivastalo
Offers Cardio-Protective Profile
“The mediated High-Density lipoprotein (HDL) elevation with Pivastalo slow the formation
of atherosclerotic plaques and reduce the residual Cardiovascular risk“
Pivastalo
The Hidden Gem
®
Luis Masana, Pitavastatin in cardio metabolic disease: therapeutic profile Masana Cardiovascular Diabetology 2013
John Jp Kastelein, Pitavastatin: an overview of the LIVES study Clin. Lipidol. (2012)

Pivastalo
Lower Drop Rate
“Pivastalo has the lowest incidence of Adverse Reports“
Pivastalo
The Hidden Gem
®
In controlled clinical studies and the open-label extension, the discontinuation rates due to adverse events were 3.9%, 3.3% and 3.7% for the 1 mg, 2 mg, and 4 mg doses of Pitavastatin respectively.